- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 173 - Related articles - All 25 versions
AM Lambeir, C Durinx, S Scharpé, I De … - Critical reviews in clinical laboratory sciences, 2003 - informahealthcare.com Laboratory of Medical Biochemistry, University of Antwerp, Universiteitsplein 1,
Wilrijk, Belgium ... Referee: Dr. Albert Adam, Faculté de Pharmace,
Université de Montréal, 2900 Blvd. Edouard—Montpetit, CP succursale ... Cited by 166 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
T Vilsbøll, JJ Holst - Diabetologia, 2004 - Springer When glucose is taken orally, insulin secretion is stim- ulated much more than
it is when glucose is infused intravenously so as to result in similar glucose
con- centrations. This effect, which is called the incretin ef- fect and is ... Cited by 145 - Related articles - BL Direct - All 7 versions
DJ Drucker - eid, 2003 - informahealthcare.com Incretins are peptide hormones, exemplified by glucose-dependent insulino-
tropic peptide and glucagon-like peptide 1 that are released from the gut in
response to nutrient ingestion and enhance glucose-stimulated insulin ... Cited by 118 - Related articles - All 6 versions
- ►diabetesjournals.org T Hansotia, LL Baggio, D Delmeire, SA Hinke, … - Diabetes, 2004 - Am Diabetes Assoc Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1
(GLP-1) are gut-derived incretins that potentiate glucose clearance following
nutrient ingestion. Elimination of incretin receptor action in GIPR −/− ... Cited by 110 - Related articles - BL Direct - All 13 versions
- ►eje-online.org [PDF] MK Reimer, JJ Holst, B Ahren - European Journal of Endocrinology, 2002 - EFES Objectives: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme,
dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of
diabetes. We examined the long-term influence of a selective, orally active ... Cited by 107 - Related articles - BL Direct - All 9 versions
CF Deacon, B Ahrén, JJ Holst - eid, 2004 - informahealthcare.com Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing
interest to both diabetologists and the pharmaceutical industry alike, as they
may become established as the next member of the oral antidiabetic class of ... Cited by 102 - Related articles - All 7 versions
CF Deacon - Regulatory peptides, 2005 - Elsevier The incretin hormones, glucose-dependent insulinotropic peptide (GIP) and
glucagon-like peptide-1 (GLP-1) are secreted from endocrine cells located in the
intestinal mucosa, and act to enhance meal-induced insulin secretion. GIP ... Cited by 70 - Related articles - All 6 versions
- ►endocrinology-journals.org [PDF] CF Deacon, S Wamberg, P Bie, TE Hughes, JJ … - Journal of Endocrinology, 2002 - Soc Endocrinology The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are degraded by dipeptidyl peptidase IV (DPP
IV), thereby losing insulinotropic activity. DPP IV inhibition reduces ... Cited by 63 - Related articles - BL Direct - All 3 versions
